Table 2.
Univariate Analysis of Cases With Different Fluconazole MICa
| Clinical Characteristics | Fluconazole MIC ≥16 µg/mL N = 13 | Fluconazole <16 µg/mL N = 22 | P Value | OR (95% CI) |
|---|---|---|---|---|
| Age (years) | 42 (34–52) | 35 (29–44) | .2746 | |
| Black Race | 11 (84.6) | 18 (81.8) | 1 | 1.22 (.19–7.82) |
| Male | 10 (76.9) | 18 (81.8) | 1 | 0.74 (.14–3.99) |
| HIV positive | 11 (84.6) | 17 (77.3) | .6889 | 1.62 (.26–9.85) |
| Prior azole | 9 (69.2) | 4 (18.2) | .0042*b | 10.12 (2.04–50.16) |
| Recurrence | 4 (36.4) | 6 (35.3) | 1 | 1.05 (.22–5.09) |
| CNS complications | 5 (38.5) | 2 (9.1) | .0754* | 6.25 (1–39.09) |
| Crude mortality | 4 (36.4) | 6 (30) | 1 | 1.33 (.28–6.32) |
Abbreviations: CI, confidence interval; CNS, central nervous system; HIV, human immunodeficiency virus; MIC, minimal inhibitory concentration; OR, odds ratio; VP, ventriculoperitoneal.
a CNS complications (VP shunt, blindness or other vision loss, deafness, seizures).
b χ2 tests or Fisher exact test, α = 0.1; significant P values marked with an asterix (*).